MapLight Therapeutics (MPLT) GC receives RSU and option awards

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. reported that its General Counsel, Kristopher Hanson, received new equity awards on February 5, 2026. He acquired 7,730 shares of voting common stock through a restricted stock unit grant at a stated price of $0, bringing his directly held total to 191,582 shares.

He was also granted an employee stock option for 31,395 shares at an exercise price of $15.7 per share. One quarter of the RSUs vest on January 1, 2027, and the remainder in equal quarterly installments, while one quarter of the option vests on February 5, 2027, with the balance vesting monthly thereafter, all contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hanson Kristopher

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	31,395	$0.00	--
Grant/Award	Voting Common Stock	7,730	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 31,395 shares (Direct); Voting Common Stock — 191,582 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanson Kristopher

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/05/2026		A		7,730(1)	A	$0(2)	191,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		31,395		(3)	02/04/2036	Voting Common Stock	31,395	$0	31,395	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MapLight Therapeutics (MPLT) report for Kristopher Hanson?

MapLight Therapeutics reported that General Counsel Kristopher Hanson received new equity awards on February 5, 2026. He was granted 7,730 restricted stock units in voting common stock and an employee stock option for 31,395 shares, both structured to vest over several years of continued service.

How many MapLight Therapeutics (MPLT) shares does Kristopher Hanson hold after this Form 4?

After the reported transaction, Kristopher Hanson beneficially owns 191,582 shares of MapLight voting common stock directly. This figure reflects the addition of 7,730 shares tied to a restricted stock unit award granted on February 5, 2026, subject to the disclosed vesting schedule and continued service requirements.

What are the key terms of Kristopher Hanson’s stock option grant at MapLight Therapeutics (MPLT)?

Hanson received an employee stock option to buy 31,395 MapLight voting common shares at an exercise price of $15.7. One quarter of the underlying shares vest on February 5, 2027, with the remaining shares vesting in equal monthly installments, conditioned on his continued service to the company.

How do Kristopher Hanson’s RSUs at MapLight Therapeutics (MPLT) vest over time?

The 7,730 restricted stock units granted to Kristopher Hanson vest over multiple dates. One quarter vests on January 1, 2027, and 1/16 of the RSUs vest on each subsequent April 1, July 1, October 1, and January 1, assuming he continues serving through each vesting date.

What role does Kristopher Hanson hold at MapLight Therapeutics (MPLT) in this insider filing?

In this insider filing, Kristopher Hanson is identified as an officer of MapLight Therapeutics, serving as General Counsel. The Form 4 reports equity compensation awards granted to him, including restricted stock units and a stock option, both subject to multi-year vesting linked to ongoing service with the company.